The COVID-19 pandemic demonstrated the ingenuity of American life-sciences enterprises, which introduced effective vaccines and therapeutics in record time, within a year of the virus’s discovery.
America’s world-leading life-sciences innovation system is a product of myriad policies, but as Stephen Ezell writes in InsideSources, a critical yet all-too-often overlooked one is the Bayh-Dole Act, which enables the commercialization of federally funded research and development by affording universities rights to intellectual property generated from that funding.
Unfortunately, a determined group of civil society activists who oppose the U.S. public-private system of drug innovation are trying again to undermine this critical policy.
